Home > PJ > Onlooker

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 267 No 7176 p796
1 December 2001

This article
Reprint
Photocopy

Onlooker

Depression examined [more]
Museums and culture [more]
Discovering Drake [more]


Depression examined

Depression is a touchy topic. Whenever I mention it I can almost guarantee hearing from a correspondent that I do not know what I am talking about.

The argument has two sides, and it is sheer cowardice to avoid touching on a subject that tends to arouse fierce controversy because it is intensively subjective in nature. Similarly, anyone mentioning the Taliban, Islam or Northern Ireland politics stands to raise someone's hackles. Nevertheless these topics must be openly debated, or they will continue to rankle in secret. The thing to do is to gird up one's loins like the old prophets and wade in regardless. The thing to avoid is arrogance.

There is inevitably much written and spoken about depression, since it has become a disability affecting many millions of people to a lesser or greater degree. The term is used in everyday conversation to describe a downswing of mood, something to which all of us are liable during our social interactions. When it involves severe emotional upsets producing deep sadness and hopelessness, with a lowered self-esteem, behavioural disturbances, loss of interest in the environment and possibly loss of sleep and appetite, depression calls for remedies. In the ultimate case suicidal thoughts and even attempts at self-harm must be taken extremely seriously.

Why women are two to three times as likely to suffer clinical depression as men is uncertain. It may reflect social and employment disabilities, which remain a common injustice of our social organisation. It seems certain that one depressive episode in a woman is often the forerunner of more, whereas in men this is not usual.

Arguments over the best way of combating depression have multiplied in recent years. One approach now thoroughly discredited is to tell the sufferer to pull himself or herself together and cheer up. This does not work. It is agreed that pharmacological intervention, though perhaps effective for a short period, is usually ineffective and sometimes hazardous. A paper published in the Journal of the American Medical Association for 10 October emphasises the frequent relationship between depression and certain other medical illnesses. Clinicians have in the past been inclined to attribute the patient's feeling of despair to a sense of vulnerability, fear and diminished self-esteem. But this view needs reconsideration in the light of evidence that depression may be an independent risk factor that contributes to the development of ischaemic heart disease and increased cardiac mortality. Indeed, depression may be part of the aftermath of a myocardial infarction, and need not be severe in order to play its part in the syndrome. Depression coexisting with other illnesses may impair recovery and rehabilitation as well as increase the risk of chronic morbidity and mortality

An editorial in the British Medical Journal for 27 October comments that a World Health Organization study of psychological disorders appearing in general health care in 14 countries shows that patients suffering major depression may be treated with sedatives as well as antidepressants, despite a finding that antidepressant treatment usually brings better results. It is argued that prescribing drugs is not the solution, but that the whole process of health care needs to be enhanced. Improved general care from co-operative primary care workers enhances the patient's ability to function in society, which is the main objective. It is to be hoped that those organisations providing patient care will respond to the urgent problem of millions of individuals world-wide who are affected by major depressive illness.

Back to Top


Museums and culture

There has been a vigorous reaction to the news that the Council of the Royal Pharmaceutical Society plans to cut down on funding its museum in the interests of economy, so that public access will end. As a professional body, the Society should concern itself with the whole background of pharmacy, including its history. By downgrading cultural activities it could reduce us all to the status of shopkeepers, and eventually show us as unworthy to take our place among the health care professional bodies devoted to the interests of doctors, nurses and scientists. We should remember we are peers in that assembly and keep our prestige alive.

The word museum is derived from the Greek mouseion, meaning "seat of the Muses". It has been defined as a collection of natural, scientific or other curiosities or works of art. That makes it a cultural and educational institution. The first building to be known as a museum was the university establishment erected at Alexandria in about 300BC by Ptolemy Soter. Ptolemy was celebrated as one of Alexander the Great's most successful generals, and when Alexander died in 323BC Ptolemy was made governor of Egypt. He assumed the royal title there in 305BC.

The name "soter" means saviour. The rise in cultural and commercial importance of the city of Alexandria under Ptolemy's governance was indeed the salvation of that ancient city. The survival of our own museum may be the key to the salvation of our professional organisation, and I am convinced we should walk warily in seeking to reduce its influence on intelligent society.

Back to Top


Discovering Drake

In 1595 Queen Elizabeth sent Sir Francis Drake in charge of an expedition to the West Indies, with Sir John Hawkins as his second-in-command. Hawkins was a sick man, and when the expedition had reached a position near Porto Rico he died. Drake, too, was taken sick with dysentery, and he died while in the bay off Porto Bello, on his ship the Defiance, on 28 January 1596. Next day his body, confined in a lead casket, was buried at sea a few miles off shore.

Since then, several attempts have been planned to try to recover Drake's body and return it to his native Plymouth. In 1883 there was a report that an expedition was to be sent to dredge up the remains of the hero, but the idea was relinquished as impracticable. Porto Bello bay, off Panama, is a relatively small area of ocean, some 40 metres deep, but swept periodically by hurricanes. Information regarding the position where Drake was committed to the deep has always been imprecise, obtainable only from the ship's log. There must in any event be considerable doubt whether his lead coffin remains in the place where it was dropped four centuries ago. It is likely to have been corroded and dispersed many years ago.

Nevertheless, according to my local press, yet another attempt to find the relic is planned for 2003, possibly financed by corporations and individuals on both sides of the Atlantic. At the same time, the expeditions plans to discover the wrecks of two ships, the Elizabeth and the Delight, which were parts of Drake's Caribbean fleet. Among special plans that are being pioneered to meet the enormous challenge is the use of a high-sensitivity chemical analysis equipment which is believed capable of isolating the lead from background minerals in the ocean and so pinpoint the Drake casket. The chances of locating Drake appear to be minute.

It is a strange commentary on human nature that anyone should wish to disturb the celebrated old Devonian from his natural element after 400 long years. Or so it appears to me.

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal